These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25172933)

  • 1. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.
    Gehrke I; Bouchard ED; Beiggi S; Poeppl AG; Johnston JB; Gibson SB; Banerji V
    Clin Cancer Res; 2014 Sep; 20(18):4861-72. PubMed ID: 25172933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
    Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N
    Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Nampt inhibitor FK866 mimics vitamin B3 deficiency by causing senescence of human fibroblastic Hs68 cells via attenuation of NAD(+)-SIRT1 signaling.
    Song TY; Yeh SL; Hu ML; Chen MY; Yang NC
    Biogerontology; 2015 Dec; 16(6):789-800. PubMed ID: 26330291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
    Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
    Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells.
    Thakur BK; Dittrich T; Chandra P; Becker A; Lippka Y; Selvakumar D; Klusmann JH; Reinhardt D; Welte K
    Biochem Biophys Res Commun; 2012 Aug; 424(3):371-7. PubMed ID: 22728882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
    Hasmann M; Schemainda I
    Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
    Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
    Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
    Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
    BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
    Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
    Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.
    Cagnetta A; Caffa I; Acharya C; Soncini D; Acharya P; Adamia S; Pierri I; Bergamaschi M; Garuti A; Fraternali G; Mastracci L; Provenzani A; Zucal C; Damonte G; Salis A; Montecucco F; Patrone F; Ballestrero A; Bruzzone S; Gobbi M; Nencioni A; Cea M
    Clin Cancer Res; 2015 Sep; 21(17):3934-45. PubMed ID: 25964294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotinamide phosphoribosyl transferase regulates cell growth via the Sirt1/P53 signaling pathway and is a prognosis marker in colorectal cancer.
    Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Qin L; Pan YL
    J Cell Physiol; 2019 Apr; 234(4):4385-4395. PubMed ID: 30191976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
    Ogino Y; Sato A; Uchiumi F; Tanuma SI
    Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
    Nagaya M; Hara H; Kamiya T; Adachi T
    Arch Biochem Biophys; 2019 Nov; 676():108155. PubMed ID: 31628926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.
    Nencioni A; da Silva RF; Fraga-Silva RA; Steffens S; Fabre M; Bauer I; Caffa I; Magnone M; Sociali G; Quercioli A; Pelli G; Lenglet S; Galan K; Burger F; Vázquez Calvo S; Bertolotto M; Bruzzone S; Ballestrero A; Patrone F; Dallegri F; Santos RA; Stergiopulos N; Mach F; Vuilleumier N; Montecucco F
    Thromb Haemost; 2014 Feb; 111(2):308-22. PubMed ID: 24196571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.
    Thakur BK; Dittrich T; Chandra P; Becker A; Kuehnau W; Klusmann JH; Reinhardt D; Welte K
    Int J Cancer; 2013 Feb; 132(4):766-74. PubMed ID: 22815158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
    Pittelli M; Cavone L; Lapucci A; Oteri C; Felici R; Niccolai E; Amedei A; Chiarugi A
    Immunol Cell Biol; 2014 Feb; 92(2):191-9. PubMed ID: 24275857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.
    Zoppoli G; Cea M; Soncini D; Fruscione F; Rudner J; Moran E; Caffa I; Bedognetti D; Motta G; Ghio R; Ferrando F; Ballestrero A; Parodi S; Belka C; Patrone F; Bruzzone S; Nencioni A
    Exp Hematol; 2010 Nov; 38(11):979-88. PubMed ID: 20696207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
    Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
    Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
    Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
    J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
    Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.